COMPANY
Xilio Therapeutics
Xilio Therapeutics is a clinical-stage biotechnology company developing masked immuno-oncology (I-O) therapies for cancer. From company website Source · Oct 12, 2026
Since the raise (Feb 11, 2026): 2 of 2 open jobs were first seen after it.
Hiring
| Title | Location (from posting) | Employer posted | First seen |
|---|---|---|---|
| Senior Scientist, Cell Pharmacology | Waltham, MA | Oct 1, 2026 | Oct 9, 2026 |
| SVP, Immunology | Waltham, MA | Jul 30, 2026 | Oct 9, 2026 |
Timeline
- Board tracked Radar started tracking this company’s job board (2 open jobs at last check). source ↗
- Raise Follow-on offering: $40M (total, as published), announced Feb 11, 2026. Source: SEC filing. source ↗
- Partnership Partnership / licensing: upfront not published; stated deal value $17.5M (kept separate from upfront), announced Sep 9, 2025. Source: SEC filing. source ↗
- Raise Follow-on offering: $150M (up to, as announced), announced Jun 5, 2025. Source: company release on GlobeNewswire. source ↗
- Raise Follow-on offering: $50M (total, as published), announced Jun 2, 2025. Source: SEC filing. source ↗
- Partnership Partnership / licensing: $52M (upfront, as published), announced Feb 12, 2025. Source: SEC filing. source ↗
Open jobs 2
| Title | Location (from posting, not HQ) | Employer posted | First seen | Level |
|---|---|---|---|---|
| Senior Scientist, Cell Pharmacology | Waltham, MA | Oct 1, 2026 | Oct 9, 2026 | Senior |
| SVP, Immunology | Waltham, MA | Jul 30, 2026 | Oct 9, 2026 | Executive |
Funding
- Follow-on offering: $40M (total, as published), announced Feb 11, 2026. Source: SEC filing. source ↗
- Follow-on offering: $150M (up to, as announced), announced Jun 5, 2025. Source: company release on GlobeNewswire. source ↗
- Follow-on offering: $50M (total, as published), announced Jun 2, 2025. Source: SEC filing. source ↗
- Partnership / licensing: upfront not published; stated deal value $17.5M (kept separate from upfront), announced Sep 9, 2025. Source: SEC filing. source ↗
- Partnership / licensing: $52M (upfront, as published), announced Feb 12, 2025. Source: SEC filing. source ↗
Raises and investors new
- InvestorListed in the portfolio of Bain Capital Life Sciences (captured Oct 12, 2026). portfolio page ↗
Connect
See your connections at Xilio Therapeutics on LinkedIn (search by name, results not checked)